Shots:

• The approval is based on SUSTAIN 6 CVOT study assessing Ozempic (0.5mg /1mg- inj.) vs PBO + SOC in 3297 patients with T2D with established CVDs
• The SUSTAIN 6 study results: @2yrs. 26% reduction in risk of MACE; primary composite outcome (6.6% vs 8.9%)
• Additionally- Rybelsus (semaglutide- 7mg/14mg) prescribing information has been updated in section 14 (clinical studies) to include an analysis from 1EPs of the PIONEER 6 CVOT study demonstrating the hazard ratio for time to first three-component MACE

Click here ­to­ read full press release/ article | Ref: Novo Nordisk | Image: The Pharma Letter